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Abstract
Background Bone invasive skull base meningiomas are a
subset of meningiomas that present a unique clinical challenge
due to brain and neural structure involvement and limitations
in complete surgical resection, resulting in higher recurrence
and need for repeat surgery. To date, the pathogenesis of
meningioma bone invasion has not been investigated. We
investigated immunoexpression of proteins implicated in bone
invasion in other tumor types to establish their involvement in
meningioma bone invasion.
Methods Retrospective review of our database identified
bone invasive meningiomas operated on at our institution
over the past 20 years. Using high-throughput tissue micro-
array (TMA), we established the expression profile of osteo-
pontin (OPN), matrix metalloproteinase-2 (MMP2), and
integrin beta-1 (ITGB1). Differential expression in tumor
cell and vasculature was evaluated and comparisons were
made between meningioma anatomical locations.
Results MMP2, OPN, and ITGB1 immunoreactivity was cy-
toplasmic in tumor and/or endothelial cells. Noninvasive
transbasal meningiomas exhibited higher vascular endothelial
cell MMP2 immunoexpression compared to invasive menin-
giomas. We found higher expression levels of OPN and
ITGB1 in bone invasive transbasal compared to noninvasive
meningiomas. Strong vascular ITGB1 expression extending
from the endothelium through the media and into the adven-
titia was found in a subset of meningiomas.
Conclusions We have demonstrated that key proteins are
differentially expressed in bone invasive meningiomas and
that the anatomical location of bone invasion is a key
determinant of expression pattern of MMP1, OPN, and
ITGB1. This data provides initial insights into the patho-
physiology of bone invasion in meningiomas and identifies
factors that can be pursued as potential therapeutic targets.
Keywords Bone invasion . Integrins . Matrix
metalloproteinase . Meningioma . Osteopontin . Transbasal
meningioma
Introduction
Meningiomas are dural-based intracranial neoplasms that are
thought to arise from arachnoid cap cells. The majority of
meningiomas are benign tumors with only approximately
5 % exhibiting features of malignancy [2]. The World Health
Organization (WHO) classifies meningiomas into three grades,
with grade I comprising 90 % of the tumors and exhibiting
benign histopathological features, grade II showing atypical
features, and grade III having anaplastic or malignant features
[39]. Histopathological features associated with aggressive be-
havior include increased cell density, a higher nuclear-to-
cytoplasmic ratio, a sheet-like growth pattern, prominent nu-
cleoli, elevated mitotic index, and necrosis. The presence of
brain invasion is a feature considered to predict aggressive
clinical behavior and recurrence, and is more recently used as
a diagnostic criterion for WHO grade II designation [39].
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A subset of meningiomas invade bone, create significant
hyperostosis, and infiltrate adjacent neural and soft tissue
structures [2, 5, 34]. In such cases, the proportion of the
tumor growing in the bone and soft tissues can in fact be
much larger than the intradural component, suggesting pref-
erential bony tropism. Bone invasion is not factored into the
WHO criterion for grading of meningiomas, however, the
extent of bone invasion can bear directly on the clinical
behavior of meningiomas, and more importantly, patient
outcome. Bone-invasive skull base meningiomas pose a
specific clinical challenge, as incomplete tumor resection
carries both an increased risk of compromise of vital vascu-
lar and neural structures in addition to the risk of recurrence.
To date, there have been no studies that focus on the path-
ophysiology of bone invasion and bone tropism in meningio-
mas. Integrins, OPN, and MMPs are thought to play key
regulatory roles in bone invasion and osteolytic metastasis in
other tumors such as breast, prostate, and lung [7–9, 13–15, 20,
22, 32, 50]; however, what role, if any, these molecules play in
the bony tropism of meningiomas is not known. As a first step
toward understanding the molecular mechanisms of bone in-
vasion, we focused our study on distinct clinical subpopula-
tions of skull base meningiomas that exhibit characteristic bone
tropism. Based on clinical, radiological, and surgical character-
istics, we defined two categories of skull base bone-invasive
meningiomas: spheno-orbital and transbasal anterior skull base
meningiomas, with their control counterparts being sphenoid
wing and noninvasive anterior skull basemeningiomas, respec-
tively. We used TMA to analyze the expression profile of
MMP2, OPN, and ITGB1 in these tumors.
Materials and methods
Tumor samples
Following institutional research ethics board approval, we
reviewed a database of all surgically resected meningiomas
from the past 20 years at our institution. Radiological and
surgical criteria were used to select bone-invasive spheno-
orbital or transbasal anterior skull base tumors and their
control counterparts, sphenoid wing and noninvasive ante-
rior skull base meningiomas, respectively. We chose to
study only WHO grade I meningiomas to avoid bias due
to tumor grade. Demographic data representing bone-
invading and noninvading skull base meningiomas are sum-
marized in Table 1.
TMA construction
Stained slides and formalin-fixed, paraffin-embedded, tissue
specimens were obtained from our archives, and original
diagnoses were reviewed by neuropathology (SC). Regions
of representative tumor were identified on the slides and the
corresponding areas of tissue circled on paraffin blocks. TMA
construction was performed with a semi-automated tissue
arrayer (Pathology Devices, Westminster, MD, USA) using
a 1.5-mm coring needle. The sample cores were embedded in
a single paraffin block. A control hematoxylin and eosin
(H&E) stain was performed and the cores were reviewed by
neuropathology for tumor integrity.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections of 4μm were
dewaxed in xylene and brought down to water through
graded ethanol solutions. Antigen retrieval was achieved
by incubation in citrate buffer of pH 6.0 for 15 min. Endog-
enous peroxidase and biotin activities were blocked with
3 % hydrogen peroxide and an avidin/biotin blocking kit,
respectively. Nonspecific reactivity was blocked by incuba-
tion with 10 % normal goat serum. Tissue was incubated at
room temperature with corresponding antibodies (ITGB1,
Abcam; OPN, Lab Vision; MMP2, Lab Vision, and CD31,
Lab Vision) with previously optimized concentrations. This
was followed by incubation with a biotinylated secondary
antibody (Vector labs, Burlingame, CA, USA) for 30 min
and horseradish peroxidase-conjugated Ultra Streptavidin
labeling reagent (ID Labs, London, ON) for 30 min. After
washing in Tris buffered solution (TBS), color development
Table 1 Demographic data representing meningiomas in the present study
Meningioma location n Female Male Age Follow-up (months) Mass effect Seizure Diplopia Visual acuity
Spheno-orbital invasive 8 6 2 48.3 31 (2–68) 8 (100 %) 1 (13 %) 1 (13 %) 3 (38 %)
Sphenoid wing noninvasive 18 13 5 55.4 33 (0–71) 17 (94 %) 5 (28 %) 1 (6 %) 4 (22 %)
Transbasal invasive 10 6 4 53.4 90 (0–212) 10 (100 %) 2 (20 %) 2 (20 %) 5 (10 %)
Transbasal noninvasive 23 16 7 42.5 28 (0–194) 22 (96 %) 7 (30 %) 2 (9 %) 8 (35 %)
All invasive 18 12 6 56.8 52 (0–212) 21 (100 %) 3 (14 %) 3 (14 %) 8 (38 %)
All noninvasive 41 29 12 49 30.5 (0–194) 39 (95 %) 12 (29 %) 3 (7 %) 12 (29 %)
Total 59 41 18 52.9 41.3 60 (97 %) 15 (24 %) 6 (10 %) 20 (32 %)
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was done with NovaRed solution (Vector Labs Cat# SK-
4800). Counterstaining was performed with Mayer’s hema-
toxylin. The slides were then dehydrated in graded ethanol
solutions, cleared in xylene, and mounted in Permount
(Fisher, Pittsburg, PA, USA, cat# SP15-500).
Microscopy and analysis
The slides were scanned and visualized using the MIRAX
digital slide scanning application (Carl Zeiss MicroImaging
GmbH, Jena, Germany). The immunohistochemical expres-
sion of OPN, ITGB1, and MMP-2 were semi-quantitatively
scored for intensity and percentage of immunoreactive cells.
Intensity was graded from 0 to 2 (0: none, 1: mild/moderate,
2: strong), and percentage was scored from 0 to 3 (0: none,
1: <25 %, 2: 25–50 %, 3: >50 %). The intensity and
percentage scores were then combined to produce a com-
posite immunoscore [36]. Where there was more than one
specimen available, an average of the immunoscores for the
specimens was calculated.
Statistical analysis
Student’s t test assuming unequal variances was used to
evaluate differences between groups. A p value of <0.05
was assumed to be significant.
Results
Clinicopathological correlations
Patient demographics and clinical information including
pattern of tumor invasion, presenting symptoms, patho-
logical grade, radiological data, and follow-up informa-
tion was recorded as summarized in Table 1. No
differences were found in patient age, sex, meningioma
progression, or pathological grade between the two skull
base bone-invasive meningioma groups and their control
counterparts.
Immunohistochemical analysis of MMP2, OPN, and ITGB1
MMP2
MMP2 was expressed to a variable degree in tumor cell
cytoplasm and the immunoscores of MMP2 tumor expres-
sion showed no significant difference between spheno-
orbital tumors and the control sphenoid wing tumors and
between transbasal and anterior skull base control meningi-
omas (Table 2). MMP2 expression within tumor vessels was
restricted to the endothelium and did not involve the media
or adventitia (Table 2). There was significantly lower vas-
cular immunoexpression by bone-invasive transbasal
tumors compared to control anterior skull base (p00.004
one-tailed) (Fig. 1a, b).
OPN
OPN was expressed to a variable degree in tumor cell
cytoplasms with the majority of tumors showing only low
levels of expression. The immunoscores of OPN in tumor
cells showed no significant difference between spheno-
orbital tumors and the control sphenoid wing tumors and
between transbasal and anterior skull base control meningi-
omas (Table 2). Vessels demonstrated OPN immunoreactiv-
ity, found within the vascular media not the intima or
adventitia (Fig. 1d). While statistical comparisons of inva-
sive spheno-orbital vascular to controls failed to reach sig-
nificance (Table 2), the comparison of invasive transbasal
vascular staining to controls demonstrated a significantly
greater immunoscore for OPN in the invasive group of
tumors (p00.037 one-tailed) (Table 2).
ITGB1
ITGB1 was expressed to a variable degree within the cyto-
plasm of tumor cells. The immunoscore of ITGB1 expres-
sion within tumor cells showed no significant difference
between spheno-orbital tumors and the control sphenoid
wing tumors (Table 2). However, there was significantly
Table 2 Immunohistochemical (IHC) staining scores (mean ± SD) of MMP2, OPN, and ITGB1 in ISB (invasive skull base), NISB (noninvasive
skull base), IS (invasive sphenoid wing), and NIS (noninvasive sphenoid wing) meningiomas
Tumor Vessel
IHC stain ISB NISB IS NIS ISB NISB IS NIS
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
MMP2 1.8±3.9 2.5±1.8 1.6±0.6 1.4±1.9 4±8 6±0 * p00.004 6±0 5.2±3.2
OPN 2.3±7.6 1.7±3.7 2.4±3.8 2.4±6.5 4.3±6.2 2.3±4.3 * p00.037 4.2±5.8 3.67±6.4
ITGB1 4.6±6.2 2.5±5.5 * p00.035 2.6±4.6 4.2±6.1 5.3±1.5 5±3 4.2±5.8 5.5±2.3
Asterisk (*) indicates statistically significant differences
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greater ITGB1 expression by invasive transbasal tumor cells
over anterior skull base controls (p 0 0.035 one-tailed)
(Fig. 1e, f). Vessels within the tumor demonstrated high
levels of ITGB1 in multiple layers extending from the
endothelium through the media and into the adventitia
(Fig. 1h). Nonetheless, immunoscores showed no difference
between the vascular expression of either spheno-orbital or
transbasal tumors and their respective controls (Table 2).
Discussion
Meningiomas make up approximately a one-fourth of all in-
tracranial tumors and the WHO identifies 12 distinct
histopathological subtypes [2, 12]. The molecular mechanisms
of tumor growth and malignant progression are poorly under-
stood and research results have been discordant. This is in part
due to the fact that meningiomas are a large heterogeneous
group of tumors classified histologically without a molecular
or genetic basis [29]. Focusing on studying specific clinical
subclasses of meningiomas, as we have done with bone inva-
sion, can potentially help eliminate the heterogeneity in the
studies and improve our understanding of the biology of me-
ningiomas. We examined the differential expression profile of
MMP2, OPN, and ITGB1 in two subclasses of bone-invasive
meningiomas, spheno-orbital and transbasal anterior skull
base, and established a distinct anatomical basis to the expres-
sion profile of these known bone-modulating factors.
Fig. 1 Immunohistochemical
expression of MMP2, OPN, and
ITGB1 in bone invasive and
noninvasive meningiomas
(original magnification ×400).
a Low vascular MMP
immunoexpression in a bone-
invading transbasal meningio-
ma. b High vascular MMP im-
munoreactivity in a
noninvading skull base menin-
gioma. The arrows indicate
vascular immunostaining. c
Low vascular OPN immunoex-
pression in a noninvading skull
base meningioma. d High vas-
cular OPN immunopositivity in
a bone-invading transbasal me-
ningioma. The arrows indicate
vascular immunostaining. e
Low tumoral ITGB1 immuno-
reactivity in a noninvading
skull base meningioma. f High
tumoral ITGB1 immunoexpres-
sion in a bone-invading trans-
basal meningioma. g Low
vascular ITGB1 immunoposi-
tivity in a noninvading skull
base meningioma. h High vas-
cular ITGB1 immunoreactivity
in a bone-invading transbasal
meningioma in multiple layers
extending from the endothelium
through the media and into the
adventitia. The arrows indicate
vascular immunostaining
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MMP2
MMPs are a family of zinc-dependent peptidases that medi-
ate degradation of extracellular matrix components. MMPs
are implicated in tumor cell growth, invasion, and metastasis
[11]. The biological role and functional contribution of
MMPs is complex and their role in meningiomas is far from
established. Previous studies have focused on establishing
the role of MMP2 in meningiomas, in particular as it relates
to tumor recurrence, brain invasion, and peritumoral edema,
and the data is conflicting [10, 19, 21, 23, 24, 26, 28–31,
48]. Though some studies found higher MMP2 expression
levels in recurrent meningiomas [28, 48], others have found
no association between meningioma grade and MMP2 levels
[29]. No correlation between MMP2 expression level and
brain-invasive potential of meningiomas has been found to
date [23, 24, 26]. Studies focused on the predictive potential of
MMP2 on meningioma peritumoral edema have been contra-
dictory, with Paek et al. [30] suggesting a positive association,
whereas Panagopolous et al. [31] noted no such association.
Yet Jaalinoja et al. [19] found noMMP-2 expression in benign
meningiomas altogether.
MMP2 expression has been shown to vary with different
meningioma histological subtypes [12, 37]. Rooprai et al. [37]
reported the weakest MMP2 expression in meningothelial
meningiomas, with the fibroblastic subtype exhibiting the
strongest MMP2 expression. Fevre-Montange, using micro-
array analysis of fibroblastic and meningothelial meningio-
mas, found MMP2 to be one of the three signature genes that
distinguished fibroblastic meningiomas, with the other two
signature factors being tenascin and fibulin-1 (FBLN1) [12].
However, others have found no association between menin-
gioma subtype and MMP2 immunoexpression [28, 48]. The
variability in results of MMP2 is in part due to meningiomas
being a large heterogeneous group of tumors, classified histo-
logically without a molecular or genetic basis and in part due
to lack of uniformity in methodology, including use of anti-
bodies and immunohistochemical scoring methods [33].
We found no difference in MMP2 expression between
bone-invasive and noninvasive skull base meningiomas by
tumor cells. There is, however, a distinct upregulation in
vascular expression of MMP2 in noninvasive anterior skull
base meningiomas compared to transbasal bone invasive skull
base meningiomas. This elevated vascular MMP2 was not
seen in the spheno-orbital group, suggesting that anatomical
location of bone invasion is an important determinant of
proteins involved in regulating their growth, vascular prolif-
eration, and potentially osteolytic activity. Despite the popular
assumption that MMPs promote tumor invasion and growth, a
recent study revealed that MMP2 overexpression in astrocy-
toma cells inhibited tumor growth and increased vascular
destabilization [44]. The investigators hypothesized that
MMP2 may target the activity of other pro- and
antiproliferative factors, thereby inhibiting tumor cell prolif-
eration in vivo [44]. Our findings of higher vascular MMP2
expression in noninvasive meningiomas could potentially
point towards an inhibitory role for this matrix metalloprotei-
nase in bone invasion through vascular destabilization.
OPN
OPN has been implicated in bone invasion in a number of
cancer types and other intracranial tumors [45]. A recent
study has proposed OPN expression as a negative prognos-
tic indicator for recurrence of WHO grade I meningiomas
[42] during a mean follow-up of 23 nonrecurrent and 9
recurrent meningiomas. As WHO classification does not
include bone invasion as one of the criteria, it is unclear
from this study if the higher recurrence rate was associated
with bone invasion. Recently, Barresi et al. [3] noted OPN
expression in psammoma bodies and calcifications, but also
within noncalcified nonpsammomatous neoplastic cells of
osteoblastic meningiomas, which are benign indolent
tumors, suggesting that the findings of Tseng et al. in regard
to OPN as a potential negative prognostic indicator should
be interpreted with caution [46].
Several studies support the role of OPN in promotion of
bone invasion in other tumor types [1, 3, 4, 6, 7, 15–18, 20,
22, 25, 27, 38, 40, 41, 47, 49, 51]. First, OPN is shown to
increase bone resorption by osteoclasts in breast carcinomas
[22]. Equally, serum OPN levels and immunoexpression are
higher in breast tumors metastasized to the bone, with
antisense inhibition of OPN in human breast cancer cells
attenuating osteolytic metastasis [25, 38]. As well, melano-
ma cells with OPN expression have a higher rate of lung and
bone metastasis when injected into wild-type mice com-
pared to OPN-deficient mice [38, 40].
In the present study, similar to MMP2, OPN expression
by tumor cells was not different in bone-invasive meningi-
omas; however, a significant increase in vascular expression
of OPN was seen in transbasal anterior skull base bone-
invasive meningiomas. These results, taken together with
the MMP2 results, point to bone remodeling being a highly
vascular-dependent process and variable based on the ana-
tomical location of meningiomas.
ITGB1
Integrins are shown to mediate bone metastasis and osteoclast
activity in neoplasms of breast and prostate [4, 32, 35, 41, 43,
47, 50]. They mediate the adhesion of osteoclasts to bone
matrix in breast cancer, thereby stimulating the release of
lysosomal enzymes that trigger bone collagen degradation [47].
In our study, ITGB1 was the only one of three factors that
had a significantly higher expression in tumor cells of trans-
basal bone-invasive skull base versus anterior skull base
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noninvasive meningiomas. However, similar to MMP2 and
OPN, there was no difference in expression in spheno-orbital
bone-invasive meningiomas. Once again, these results support
the significance of anatomical location governing the differ-
ence in biology of transbasal bone invasion versus spheno-
orbital meningiomas. Of note is the striking vascular ITGB1
expression found in invasive as well as noninvasive meningi-
omas, independent of tumor location. ITGB1 stained multiple
vascular layers extending from the endothelium through the
media and into the adventitia, compared to OPN, which
stained only the endothelial cells and MMP2 that stained only
the vascular media.
Previous studies focusing on ITGB1 expression in menin-
giomas are limited to date [4]. Bello et al. [27] found higher
ITGB1 expression in atypical and malignant meningioma vas-
culature as well as tumor cells compared to benign meningio-
mas. It was noted that tumor vascular ITGB1 immunopositivity
was localized to endothelial cells. ITGB1 was also found in
vessels present in peritumoral brain tissue, suggesting ITGB1
expression in activated vasculature surrounding tumor tissue, as
normal brain tissue is not known to express ITGB1. The
significance of ITGB1-mediated pathways was also suggested
by the strong correlation between the expression of ITGB1 and
vitronectin, an ITGB1-specific ligand required for its activity
and promotion of cell migration [27]. This high expression
level of ITGB1 in meningiomas makes it a potentially suitable
therapeutic target for treatment of unresectable meningiomas.
Conclusions
This study provides initial insights into the expression
profile of proteins involved in bone invasion in skull
base bone-invasive meningiomas. Of the three factors
investigated, MMP2, OPN, and ITGB1, ITGB1 in trans-
basal anterior skull base bone-invasive meningiomas
was the only factor found to be significantly upregu-
lated. Furthermore, transbasal meningiomas demonstrate
significantly higher levels of OPN and ITGB1 expres-
sion in the tumor vasculature, suggesting a vascular-
dependent role for bone invasion in this subset of me-
ningiomas. None of the factors demonstrated significant
difference between spheno-orbital bone invasive and
their control sphenoid wing meningiomas, whether cy-
toplasmic or vascular. Our results strongly suggest that
the molecular regulators of bone tropism, osteolytic
activity, and vascular remodeling of meningiomas is
dependent on anatomical location, with transbasal ante-
rior skull base meningiomas showing a distinct differ-
ential expression pattern compared to spheno-orbital
meningiomas.
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